about
Abuse of amphetamines and structural abnormalities in the brainMechanisms of dopamine transporter regulation in normal and disease statesPotential adverse effects of amphetamine treatment on brain and behavior: a reviewDopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.Sex differences in Parkinson's diseaseIncreased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.Glial modulators as potential treatments of psychostimulant abuseVesicular integrity in Parkinson's diseaseCellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cellsPesticides, microglial NOX2, and Parkinson's diseaseThe Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Molecular implications of repeated aggression: Th, Dat1, Snca and Bdnf gene expression in the VTA of victorious male mice.Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat.Vmat2 heterozygous mutant mice display a depressive-like phenotype.Antidepressant-Like Effect of the Endogenous Neuroprotective Amine, 1MeTIQ in Clonidine-Induced Depression: Behavioral and Neurochemical Studies in Rats.The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosisExercise protects against MPTP-induced neurotoxicity in mice.Physical activities and future risk of Parkinson disease.Syntaxin 1A regulates dopamine transporter activity, phosphorylation and surface expression.Palmitoylation controls dopamine transporter kinetics, degradation, and protein kinase C-dependent regulationVMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Forced limb-use and recovery following brain injury.From genes to integrative physiology: ion channel and transporter biology in Caenorhabditis elegans.Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function miceDieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system.Susceptibility to a parkinsonian toxin varies during primate developmentAge-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degenerationDopamine transporter phosphorylation site threonine 53 regulates substrate reuptake and amphetamine-stimulated efflux.Molecular mechanisms involved in the toxic effects of polychlorinated biphenyls (PCBs) and brominated flame retardants (BFRs).Association between polychlorinated biphenyls and Parkinson's disease neuropathology.Neurochemical targets and behavioral effects of organohalogen compounds: an update.Phosphorylation of dopamine transporter serine 7 modulates cocaine analog binding.Pyrethroid pesticide-induced alterations in dopamine transporter function.Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum.alpha-synuclein and Parkinson's disease: the first roadblock.Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degenerationAlteration of dopamine uptake into rat striatal vesicles and synaptosomes caused by an in vitro exposure to atrazine and some of its metabolites.
P2860
Q22241673-0460829C-381D-4E80-9846-6F2B1BDA2FC7Q24598750-0054F484-3FDF-4638-B67A-2314FB2F0776Q24657966-04180AF3-C8EB-40CD-AB6D-4E381A55D4E8Q24815335-49587D9D-8115-43AB-975E-436C48BD2682Q27025107-BE5D3BC0-BB38-43B8-935F-12386FDD03B7Q27308109-AC47CCB2-9DB9-4476-AFA6-E8179B348BE6Q28307030-4AC422CB-CD6A-405A-862B-8CD05CCAC41CQ28385737-D10C1E30-261E-495E-9468-804FAA1FCC03Q28387863-7EBE4691-23CB-4D46-8CA7-190E251EE409Q28397585-7B1D26FC-CC9A-4CB1-9B3C-B91F2F898E09Q30430534-218D4EA0-5D23-45B3-80A4-822D9C0C0D52Q33399726-C083E030-001E-49AA-9010-D4CA2E715460Q33671819-D74F539A-5B07-4BDA-9AE4-C853EDBD34A3Q33793549-C323C65F-90C4-4ED6-B4C0-9BA54607EDC4Q33844389-61EB95B6-155E-419D-9FB2-DAAF38E9675EQ33854736-35EE3A11-784A-4C60-BA38-293951CCA6A5Q33862898-C0A81174-11B5-4CBD-BC9C-D6609A30F92EQ33907587-9CDA5815-2580-42CD-95AC-5ED6AF21D426Q34054934-C469EDE0-7F4D-4671-8C2E-9430178FF13DQ34103973-2DAD58E2-6ABC-4CC2-9DD2-E14C7A4BE5FEQ34568367-5C95877A-C12B-4A53-BB67-C551D1939EAFQ34595165-31613567-5F9F-4CF9-92BA-AFBF6D89FB46Q34673305-170B1740-CB16-4331-8D08-61780BBB5856Q35007339-AFCFB802-3DB3-4D83-840F-B51470867693Q35017630-02307734-E87C-496F-85A7-A2B6403C6098Q35094105-6263F405-0882-4592-A307-1C7AA18C1F5FQ35533526-5337C790-90B9-44D3-A566-469D321A0A2CQ35850734-ED8ABD49-F86C-4C64-8319-7C8A0FCEC22EQ35907253-3FD62884-DA15-4DB6-8EBE-E7DD379F5B37Q36081666-94F36443-FC32-49F0-96D2-2F87381DD31FQ36215945-8126E267-21BE-4FF4-B8AA-E26D7BC6AC01Q36314414-3D5B44D2-74F2-42FB-A977-DE94A5020BF8Q36315478-0F3A176B-872D-49F4-BBA7-07329A48BCCBQ36473995-6F84538F-6E50-4E6E-BFB7-7B0F3F9FFD95Q36508575-8A591BAF-2BD6-4E68-B667-25D5D56FBEB1Q36584914-1D3DEE4D-BFB1-4C6A-8001-446C05FCA8C5Q36584927-E8906E9F-D365-46EC-BBE8-BBA46E568FBFQ36663027-2969CA3C-2D1F-4560-92DF-C4B3D5C1D48CQ36691830-F2F1D567-5CD1-43DD-B01C-78A9090A9BB1Q36727046-2674FF1E-48B1-40B7-B9A7-CE0D69D9DAA2
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Dopamine transporters and neuronal injury.
@ast
Dopamine transporters and neuronal injury.
@en
type
label
Dopamine transporters and neuronal injury.
@ast
Dopamine transporters and neuronal injury.
@en
prefLabel
Dopamine transporters and neuronal injury.
@ast
Dopamine transporters and neuronal injury.
@en
P2093
P1476
Dopamine transporters and neuronal injury.
@en
P2093
P304
P356
10.1016/S0165-6147(99)01379-6
P577
1999-10-01T00:00:00Z